NIH SBIR Direct-to-Phase II (Omnibus)
Funds United States small businesses moving directly into major development when early biomedical feasibility is already established.
The NIH SBIR Direct-to-Phase II (D2PII) Omnibus allows U.S. small businesses to apply directly for Phase II-level funding without a prior NIH Phase I award, provided the company can demonstrate that Phase I-equivalent feasibility has already been established through other means. Issued under activity code R44 as a "New" application (not a renewal), D2PII awards carry the same cap as standard Phase…
Phase II-scope biomedical R&D for projects whose feasibility has been established through prior non-SBIR work (e.g. university research, foundation funding, internal R&D).
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up